Radiation therapy and serum salivary amylase in head and neck cancer

Francesca De Felice _, Mario Tombolini, Angela Musella, Francesco Marampon, Vincenzo Tombolini and Daniela Musio

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:90496-90500. https://doi.org/10.18632/oncotarget.18763

Metrics: PDF 1239 views  |   HTML 1890 views  |   ?  


Francesca De Felice1, Mario Tombolini2, Angela Musella3, Francesco Marampon4, Vincenzo Tombolini1 and Daniela Musio1

1Department of Radiotherapy, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy

2Department Organs of Sense, Policlinico Umberto I, “Sapienza”, University of Rome, Rome, Italy

3Department of Gynecology, Obstetrics and Urological Sciences, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy

4Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy

Correspondence to:

Francesca De Felice, email: [email protected]

Keywords: amylase, head and neck cancer, radiotherapy, dose, salivary glands

Received: May 07, 2017     Accepted: June 10, 2017     Published: June 28, 2017


Radiation therapy (RT) is a valid treatment option for head and neck cancer (HNC). The risk of RT-induced toxicities is significant, especially due to extended treatment fields. The raise in amylase activity is strictly dependent on the volume of salivary glands included in the irradiated target volume and it is firmly related to the dose. The aim of this review is to report the effects on salivary amylase activity after radiation exposure of salivary glands, in patients with HNC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18763